Synthesizing the Evidence for Ketamine and Esketamine in ...

Synthesizing the Evidence for Ketamine and Esketamine ... - PubMed

Ketamine and esketamine represent pharmacologically novel treatment avenues for adults with treatment-resistant depression. In addition to ...

Ketamine and esketamine represent pharmacologically novel treatment avenues for adults with treatment-resistant depression. In addition to ...

Synthesizing the evidence for ketamine and esketamine in treatment ...

Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and ...

Synthesizing the Evidence for Ketamine and Esketamine in ...

Ketamine and esketamine represent pharmacologically novel treatment avenues for adults with treatment-resistant depression. In addition to providing hope to ...

Synthesizing the Evidence for Ketamine and Esketamine in ...

In addition to providing hope to affected persons, these agents represent the first non-monoaminergic agents with proven rapid-onset efficacy in major ...

Synthesizing the Evidence for Ketamine and Esketam... - BV FAPESP

Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and ...

AJP Author Spotlight: The Evidence for Ketamine and Esketamine in ...

Roger S. McIntyre, M.D., discusses his article "Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An ...

Ketamine and esketamine in suicidal thoughts and behaviors - NCBI

Overall, there is compelling evidence for a favorable short-term benefit-risk balance with intravenous racemic ketamine but not intranasal ...

Comparative efficacy of racemic ketamine and esketamine for ...

We reviewed the peer-reviewed academic literature to synthesize evidence for the comparative efficacy and acceptability of racemic ketamine and ...

Full display page - Primo by Ex Libris

Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and ...

Ketamine and Esketamine for Treatment-Resistant Depression

... studies. REFERENCES. 1. McIntyre RS, Rosenblat JD, Nemeroff CB, et al: Synthesizing the evidence for ketamine and esketamine in treatment-resistant.

Synthesizing the Evidence for Ketamine and Esketamine in ... - Scite

Supporting: 6, Mentioning: 215 - Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on ...

IN Esketamine and IV Ketamine: Results of a multi-site observational ...

Intravenous (IV) ketamine and intranasal (IN) esketamine are novel therapies to manage treatment resistant depression within major depressive disorder ...

Extended-release ketamine tablets for treatment-resistant depression

Over the past two decades, there has been a growing evidence base demonstrating the rapid-onset antidepressant properties of ketamine in ...

Registered clinical trials investigating ketamine and esketamine for ...

While ketamine is administered off-label for psychiatric disorders, the S-enantiomer (esketamine) was synthesized into a prescription nasal ...

Efficacy and safety of ketamine and esketamine for unipolar and ...

Conclusion: While ketamine and esketamine show promising therapeutic potential, the current evidence suffers from low study quality. Enhanced ...

Music as an Intervention to Improve the Hemodynamic Response of ...

McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression ...

Untitled

Esketamine - Wikipedia

In the form of racemic ketamine, esketamine was first synthesized in 1962 and introduced for medical use as an anesthetic in 1970. ... Enantiopure esketamine was ...

Short-term ketamine use in bipolar depression - Frontiers

Intranasal ketamine's enantiomer—esketamine is a novel rapid-acting antidepressant with proven efficacy in treatment-resistant depression.